US20020025344A1 - Ionic silver complex - Google Patents

Ionic silver complex Download PDF

Info

Publication number
US20020025344A1
US20020025344A1 US09/796,242 US79624201A US2002025344A1 US 20020025344 A1 US20020025344 A1 US 20020025344A1 US 79624201 A US79624201 A US 79624201A US 2002025344 A1 US2002025344 A1 US 2002025344A1
Authority
US
United States
Prior art keywords
colloidal solution
silver
substantially non
free
ions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/796,242
Inventor
Ira Newman
David Washburn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/796,242 priority Critical patent/US20020025344A1/en
Publication of US20020025344A1 publication Critical patent/US20020025344A1/en
Priority to US10/175,260 priority patent/US20020150628A1/en
Priority to US10/383,345 priority patent/US6838095B2/en
Priority to US11/028,840 priority patent/US20050118281A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/38Silver; Compounds thereof
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A01N59/16Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/06Chelate
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/13Burn treatment

Definitions

  • This invention relates to solutions including complexed ionic silver. More particularly, it relates to solutions including complexed ionic silver wherein the solutions convey health benefits through their use or application.
  • Silver has been known to act antimicrobially as an agent in and on the body of humans as well as other animals, and to be relatively non-toxic to mammalian cells when used in the minute quantities needed to be antimicrobially effective.
  • the most effective form of silver for antimicrobial use is as ions in solution.
  • Silver ions have been shown in the past to have antibacterial, antiviral and antifungal qualities, and to contribute directly to the regeneration of tissue. While the exact method by which silver ions perform these functions is not known, it is believed that they may (1) disrupt the respiratory functions, or (2) disrupt membrane functionality of single-celled microorganisms, or (3) link to the cell's DNA and disrupt cell functions. It is not conventionally understood why silver ions appear to some to be effective at regenerating tissue, which apparently involves more than acting as an antimicrobial agent.
  • ionic silver substances have been undergoing a substantial resurgence in popularity, and are increasingly regarded as a reasonably safe and effective antimicrobial agent.
  • Silver ion substances are increasingly being used in medical applications as well as by those seeking a natural alternative to traditional antibiotic medications.
  • Ionic silver substances are being used in topical dressings to treat wounds and to prevent and treat infections. They are also being used for water supply sanitation for public utilities, for pharmaceutical equipment sanitation, and for killing germs including the germ that causes Legionnaires' Disease in the water systems of hospitals. Tooth brushes are now being introduced that release silver ions in order to fight oral bacteria.
  • free silver defined as silver ions which are not part of a complex or compound, and are therefore biologically available, are delivered at once to the body, there is only opportunity for them to perform the antimicrobial function for an instant where they make contact with the body or the oral tissue before being rendered inactive.
  • an antimicrobial ionic silver formulation has desirable characteristics that it gradually releases its silver content as free silver ions upon ingestion or upon topical application in a manner that is slow enough to sustain the antimicrobial functionality for a sufficient period of time while also being rapid enough to be substantially effective, that it facilitate mobility of the silver through the body upon oral ingestion prior to gradually releasing its silver content as available free silver ions, and that it be nontoxic to the body.
  • Topical applications of ionic silver do not require a controlled, gradual release of silver ions to the degree that internal, oral ingestion applications require it because there is a lower presence of agents with which the silver ions can bind up and form complexes or compounds upon topical exposure as compared with ingestion for internal use.
  • At least one product has been recently introduced that consists of a film dressing impregnated with a complex that gradually releases silver ions upon exposure to the body's chemistry.
  • Colloidal silver is a substance which has been in use for about a hundred years. It provides a reasonable degree of controlled release and mobility of silver ions in and on the body. Colloidal silver is apparently made up of minute particles of silver, associated with silver ions that comprise a small percentage of such particles. The mass of these particles provide a degree of controlled, gradual release of silver ions as the body's chemistry breaks down these particles.
  • the electrolysis process that is used to make most colloidal silver has substantial limitations and does not enable adequate consistency in terms of parts per million (PPM) of silver relative to the total solution by molar weight, particle size, or percentage of ions, for most desired applications. Additionally, purity of the substance is typically limited because electrolytes must usually be added to the water during the production method, the most common of which is sodium. Oxides typically form during production, often resulting in an undesirable yellow or brown color. Moreover, the potency of most electrically produced colloidal silver is inherently limited. After a concentration of approximately 5 PPM of silver (in some cases up to approximately 20 PPM of silver) is reached, the production method typically fails to continue yielding electron-deficient silver particles. The particles formed after such a concentration is reached are typically not capable of performing antimicrobial functions as do the particles that are initially produced prior to reaching this approximate level of total silver concentration (the aggregate of the complexed silver and the free, available silver in the water-based solution).
  • PPM parts per million
  • colloidal means “something suspended in a dissimilar medium,” and shelf life is, therefore, inherently limited because the colloidal silver particles gradually settle out of the water. Colloidal particles are not dissolved in the water medium; they are not in solution. The suspension is a result of, for example, Brownian motion which is insufficient to keep the particles from settling out over time. Some colloidal silver substances have stabilizing agents such as proteins added to the formula, but these tend to further hinder the availability of the silver ions to the body. What is therefore needed are compositions comprising silver ions, and methods of making and using such compositions, that address the aforementioned problems.
  • the invention relates to a substantially non-colloidal solution made by combining ingredients comprising (a) water; (b) a source of free silver ions; and (c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent.
  • a substantially non-colloidal solution made by combining ingredients comprising (a) water; (b) a source of free silver ions; and (c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent overcomes many of the limitations inherent in the aforementioned forms of ionic silver substances and has wide application in and on the body.
  • the inventive, substantially non-colloidal solution provides silver ion concentrations well above those typically provided by colloidal silver products.
  • the production method provides a typically consistent formulation.
  • the inventive formulation is highly stable, has many years of shelf life, and maintains its consistency and structure under a wide range of environmental conditions. Substantially wide concentration ranges of complexed silver are attainable without significantly compromising the desirable characteristics of the product.
  • the composition of the invention efficiently provides for substantial mobility of the silver complex through the body and for controlled decomplexing of its silver content, whereupon it gradually releases silver as available free silver ions, upon introduction of the product to the body's chemistry internally through oral ingestion or upon topical application.
  • the inventive, substantially non-colloidal solution is relatively nontoxic to the human body at typical doses.
  • the inventive substantially non-colloidal solutions are made from ingredients comprising water, a source of free silver ions; and a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent.
  • Water usable in the practice of this invention should be relatively pure. Suitable types of water include: deionized water, distilled water, reverse osmosis filtered water, reagent grade water and USP grade water suitable for use in pharmaceuticals.
  • the water is desirably substantially free of contaminants, such as parasites, pathogens, chemical contaminants, and particulate contamination.
  • the source of silver ions may be virtually any compound or complex which includes silver ions as a constituent, from which those silver ions can be obtained in order to be complexed with the recited complexing agent or to become free silver ions as part of the inventive solution.
  • Sources of silver ions comprise silver oxide, trisilver citrate, silver acetate, water soluble silver salts or any number of other sources of silver without departing from the scope of the invention.
  • the source of silver ions is silver oxide (AgO).
  • silver oxide eliminates a superfluous counter ion, hydroxide, which is innocuous since hydroxide is already present in the solution.
  • the substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent serves primarily to provide a “controlled release” of biologically active silver ions.
  • complexing agent may be taken to mean an ionic material with which silver ions are complexed in such a manner that the complexing agent forms a weak bond with the silver ions wherein the missing electron position which is a characteristic of the silver ion is filled by an electron of the complexing agent.
  • the substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent may comprise a carboxylic acid, or a primary, secondary or tertiary amine.
  • substantially non-toxic may be taken to mean that the recited complexing agent, when present in the inventive solution in usual amounts according to the invention, and when administered as part of the inventive solution in usual dosage amounts of the inventive solution, creates little or no toxic effects in a host to which the inventive solution is administered.
  • the substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent comprises amino acids or hydroxy acids.
  • the amino acids comprise glycine, alanine, valine, leucine, isoleucine, methiorine, proline, phenylalanine, tryptophan, serine, threonine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, or histidine.
  • the hydroxy acids comprise glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, or mandelic acid.
  • the citric acid comprises dibasic citrate.
  • Citrate a key constituent of the metabolic system, is aggressively drawn to the cells throughout the body and provides an efficient delivery system for spreading the silver through the body before decomplexing takes place and the silver is gradually released as available free silver ions.
  • acetic acid certain crown ethers
  • primary, secondary or tertiary amines such as ethanolamine
  • substantially non-toxic, substantially thiol-free, substantially watersoluble complexing agents are also useful.
  • the inventive substantially non-colloidal solution possesses greater than about twenty parts of silver per million parts of the non-colloidal solution.
  • PPM is defined as parts of total silver to 1,000,000 parts of the total solution including the water base and all substances contained in it by weight.
  • the substantially non-colloidal solution possesses greater than about fifty parts of total silver per million parts of the non-colloidal solution.
  • the substantially non-colloidal solution posesses greater than or equal to about one hundred parts of total silver per million parts of the non-colloidal solution. Higher parts per million of total silver are desirable, as biological effectiveness increases as PPM free silver increases.
  • 100 PPM of silver is a desirable level for the total concentration of silver because it provides a highly effective concentration of silver yet the concentration is low enough to facilitate ease of measuring and dispensing the small dosages appropriate for small children and small animals.
  • the amount of silver can vary substantially, within solubility limits, without departing from the scope of the invention, as long as the other elements are varied in relative proportion to the silver.
  • the inventive solution may be comprised of as little as about 10 PPM of silver or as much as about 10,000 PPM of silver without departing from the scope of the invention.
  • counter ions may be utilized. Such counter ions may be used to balance the charge present in the recited complexing agent, if necessary.
  • Sources for counter ions suitable for use in this invention include those conventionally known sources of counter ions. Any suitable source of counter ions may be used where the complexing agent is such that a counter ion is required to maintain the electrical stability of the silver complex, so long as the counter ion used does not compete with the silver for the complexing agent.
  • the source of counter-ions comprises potassium ions, or calcium ions.
  • the inventive non-colloidal solution possesses less than about ten weight percent of free silver based on the weight of total silver. In an aspect of the invention, the non-colloidal solution possesses less than about one weight percent of free silver based on the weight of total silver. In an aspect of the invention, the non-colloidal solution possesses less than about one-tenth of a weight percent of free silver based on the weight of total silver.
  • a relatively low amount of free silver as compared to total silver (including non-free silver or complexed silver) is retained in a non-reacted state in the inventive solution, until released over time by the equilibrium driving force. This controlled release aspect of the inventive formulation is desirable, as activity is retained over time.
  • the preferred embodiment of the invention containing a complex of citrate and silver with potassium as a counter ion, may include the following complex of ions in a solution of relatively pure water:
  • the inventive solution may be made by mixing silver oxide, citric acid and tripotassium citrate in an approximately 1*4 molar ratio, respectively, in sufficient pure water to produce a silver concentration of 100 parts per million.
  • Other formulations which result in an approximate 1:2 molar ratio to an approximate 1:20 molar ratio of silver to dibasic citrate in no way depart from the scope of the invention.
  • a preferable molar ratio (as dry ingredient or as solution) of silver to complexing agent is from about 1:1 to about 1:200, more preferably from about 1:1.5 to 1:50, most preferably from about 1:2 to about 1:20.
  • the free silver ions are present in the substantially non-colloidal solution in an anti-microbially effective amount.
  • the inventors have also produced the product following the general procedures described above but reducing the amounts of citric acid and of potassium citrate to half of the amounts described above. Numerous other variations can also be utilized with these starting ingredients provided that the ratio of citric acid to potassium citrate is generally maintained. Likewise, the amount of silver oxide may be substantially increased or decreased provided that a reasonably commensurate adjustment is made in the relative amounts of citric acid and of potassium citrate to silver oxide although, as demonstrated by the fact that the product was successfully produced upon changing the ratio of silver oxide to citric acid and to potassium citrate by 100 %, substantial latitude exists with regard to that ratio.
  • ionic silver can kill over 650 disease-causing germs.
  • the invention is absolutely harmless to the body when used in the low quantities needed for the antimicrobial action to occur, especially since the formulation provides an efficiently controlled, gradual release of free silver ions (provided that the complexing agent is nontoxic), requiring less silver ingestion in order to obtain the benefits of silver ion activity that other substances cannot render with substantially higher levels of silver ingestion.
  • Ionic silver is used for literally hundreds of conditions, including eye and ear infections, nose, sinus and gum infections, acne, sore throats, colds and flu, candida, bladder and vaginal infections, cuts and bums, many skin conditions, bug bites, fighting nail and skin fungus, healing sunburn, alleviating diaper rash and bed sores, providing a soothing skin treatment after shaving, and use as a mouth rinse.
  • Body odors are caused by bacteria in the perspiration, which is often alleviated upon application of the invention, clearly demonstrating how effectively it kills bacteria.
  • Ionic silver is also used for treating ulcers, both in fighting the bacteria that can aggravate an ulcer and in repairing the damaged stomach lining.
  • Ionic silver is used for many severe conditions as well, including, for example, tuberculosis, Epstein-Barr Virus, Lyme Disease, Legionnaires' Disease, bronchitis, chicken pox, and numerous others. There are actually few germ-related conditions, or conditions requiring the repair of tissue, for which ionic silver is not used, since many claim it is not only effective in killing most bacteria but also many if not most fungus and viruses. Some reports indicate that it is also effective against a number of parasites that might invade the body. Ionic silver is also reported by some researchers to be effective at treating cancer and HIV.
  • Ionic silver is also considered by many to be very useful in oral irrigation systems designed for consumer use, that spray a fine stream of water in the mouth, in fighting infection and healing gums. Ionic silver is even reputed to be quite effective in facilitating the growth of hair in the local area on which it is topically applied.
  • the product can readily be bottled or packaged with a variety of types of dispensers to further facilitate its usefulness.
  • a bottle with a dropper is most convenient for eye drops, ear drops and nose drops.
  • a plastic squeeze bottle can serve as a convenient dispenser for eye drops and ear drops, while the same with a nasal sprayer feature can readily facilitate use as a sinus and nasal spray.
  • a spray dispenser such as with, for instance, a pump spray, makes it very convenient to apply the product externally and also provides a convenient and efficient method for oral use and internal ingestion. By disbursing the product upon spraying it in the mouth, such a spray facilitates absorption of the formula into the blood system through the tissue lining in the mouth.
  • a spray dispenser also facilitates delivery of the product to the lungs as one may inhale while spraying the product towards the throat area. while inhaling. Because of the existence of a weak complex of silver and the existence of available free silver ions, along with the photoreactive qualities of silver, packaging should preferably be in an opaque glass container, in a stainless steel container, or in a polypropylene or polyethylene plastic container. Ideally, dispensers should be made of such materials as well.
  • the product can be used for humans as well as animals.
  • the complexing agent is a nontoxic material
  • the product is safe for children and pets.
  • the invention has a wide range of potential uses for both medical and veterinary applications.
  • the product can also be applied to surfaces for killing germs thereon. For instance, it can be sprayed on counter tops, cutting boards, toilet seats, doorknobs, telephone handsets, etc. Upon contact with germ cells, the available free silver ions should react with and kill the germ cell, causing another silver ion to be decomplexed and released from the complexing agent and be made available.
  • the invention may be utilized in both the prevention and the treatment of disease.
  • an individual may ingest the product on a daily basis as a preventative, achieving substantial levels of protection from germs, while remaining within extremely safe limits of daily and lifelong silver intake relative to the amount of silver contained in the product in the preferred embodiment.
  • an individual consuming a substantial amount of the product on a daily basis in terms of potential health benefits would, in fact, be consuming no more silver than that amount which was depleted from the diets over that period of time.
  • stir speed was turned to high and stirring continued for approximately an additional 30 minutes, filling the carboy to approximately the 18-liter mark, turning off the stirrer, opening the water input valve and stopping the water input at precisely the 19-liter mark, turning the stirrer back on to the high speed, and stirring for an additional 60 minutes.
  • Example 1 A 31-year old male and a 28-year old male who work together in the same store had both come down with a full-blown flu. Both took fifteen drops of the solution of Example 1 in an oral dose, one time, and within a day-and-a-half both were completely free of any further symptoms.
  • a one-year old male was diagnosed with a blocked tear duct in his left eye. Every day, he awoke with a green drainage that continued through the day. Two physicians recommended surgery. The boys mother administered only one drop of the solution of Example 1 in his eye each day for two days. The condition disappeared. Upon a follow-up nine months later, the condition had not returned.

Abstract

The invention relates to a substantially non-colloidal solution made by combining ingredients comprising (a) water; (b) a source of free silver ions; and (c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims priority to U.S. Provisional Patent Application No. 60/107710, filed Nov. 9, 1998.[0001]
  • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention [0002]
  • This invention relates to solutions including complexed ionic silver. More particularly, it relates to solutions including complexed ionic silver wherein the solutions convey health benefits through their use or application. [0003]
  • 2. Description of Related Art [0004]
  • Silver has been known to act antimicrobially as an agent in and on the body of humans as well as other animals, and to be relatively non-toxic to mammalian cells when used in the minute quantities needed to be antimicrobially effective. The most effective form of silver for antimicrobial use is as ions in solution. Silver ions have been shown in the past to have antibacterial, antiviral and antifungal qualities, and to contribute directly to the regeneration of tissue. While the exact method by which silver ions perform these functions is not known, it is believed that they may (1) disrupt the respiratory functions, or (2) disrupt membrane functionality of single-celled microorganisms, or (3) link to the cell's DNA and disrupt cell functions. It is not conventionally understood why silver ions appear to some to be effective at regenerating tissue, which apparently involves more than acting as an antimicrobial agent. [0005]
  • During recent years, ionic silver substances have been undergoing a substantial resurgence in popularity, and are increasingly regarded as a reasonably safe and effective antimicrobial agent. Silver ion substances are increasingly being used in medical applications as well as by those seeking a natural alternative to traditional antibiotic medications. Ionic silver substances are being used in topical dressings to treat wounds and to prevent and treat infections. They are also being used for water supply sanitation for public utilities, for pharmaceutical equipment sanitation, and for killing germs including the germ that causes Legionnaires' Disease in the water systems of hospitals. Tooth brushes are now being introduced that release silver ions in order to fight oral bacteria. [0006]
  • However, delivering silver ions for utilization in or on the body is a challenge because silver ions are electrically attracted to a host of substances in and on the body, resulting in the silver ions rapidly forming complexes or compounds wherein the ion is no longer available to perform the appropriate antimicrobial function. A controlled, gradual release of silver ions is desirable for achieving appropriate use of silver ions in or on the body in order to offset this phenomenon, and is especially challenging for antimicrobial use of silver ions internally such as upon oral ingestion. If free silver, defined as silver ions which are not part of a complex or compound, and are therefore biologically available, are delivered at once to the body, there is only opportunity for them to perform the antimicrobial function for an instant where they make contact with the body or the oral tissue before being rendered inactive. [0007]
  • The desirable characteristics of an antimicrobial ionic silver formulation are that it gradually releases its silver content as free silver ions upon ingestion or upon topical application in a manner that is slow enough to sustain the antimicrobial functionality for a sufficient period of time while also being rapid enough to be substantially effective, that it facilitate mobility of the silver through the body upon oral ingestion prior to gradually releasing its silver content as available free silver ions, and that it be nontoxic to the body. [0008]
  • Topical applications of ionic silver do not require a controlled, gradual release of silver ions to the degree that internal, oral ingestion applications require it because there is a lower presence of agents with which the silver ions can bind up and form complexes or compounds upon topical exposure as compared with ingestion for internal use. At least one product has been recently introduced that consists of a film dressing impregnated with a complex that gradually releases silver ions upon exposure to the body's chemistry. [0009]
  • Previously, some silver-containing chemical substances, such as silver nitrate, have been utilized in an effort to gain the antimicrobial benefits of silver ions, but these substances have proven minimally effective in or on the body because they immediately deliver all of their silver content as free silver ions. Some such substances, such as silver nitrate, are undesirably toxic to the human body when administered in typical doses. [0010]
  • Colloidal silver is a substance which has been in use for about a hundred years. It provides a reasonable degree of controlled release and mobility of silver ions in and on the body. Colloidal silver is apparently made up of minute particles of silver, associated with silver ions that comprise a small percentage of such particles. The mass of these particles provide a degree of controlled, gradual release of silver ions as the body's chemistry breaks down these particles. [0011]
  • However, the electrolysis process that is used to make most colloidal silver has substantial limitations and does not enable adequate consistency in terms of parts per million (PPM) of silver relative to the total solution by molar weight, particle size, or percentage of ions, for most desired applications. Additionally, purity of the substance is typically limited because electrolytes must usually be added to the water during the production method, the most common of which is sodium. Oxides typically form during production, often resulting in an undesirable yellow or brown color. Moreover, the potency of most electrically produced colloidal silver is inherently limited. After a concentration of approximately 5 PPM of silver (in some cases up to approximately 20 PPM of silver) is reached, the production method typically fails to continue yielding electron-deficient silver particles. The particles formed after such a concentration is reached are typically not capable of performing antimicrobial functions as do the particles that are initially produced prior to reaching this approximate level of total silver concentration (the aggregate of the complexed silver and the free, available silver in the water-based solution). [0012]
  • The term colloidal means “something suspended in a dissimilar medium,” and shelf life is, therefore, inherently limited because the colloidal silver particles gradually settle out of the water. Colloidal particles are not dissolved in the water medium; they are not in solution. The suspension is a result of, for example, Brownian motion which is insufficient to keep the particles from settling out over time. Some colloidal silver substances have stabilizing agents such as proteins added to the formula, but these tend to further hinder the availability of the silver ions to the body. What is therefore needed are compositions comprising silver ions, and methods of making and using such compositions, that address the aforementioned problems. [0013]
  • SUMMARY OF THE INVENTION
  • In an aspect, the invention relates to a substantially non-colloidal solution made by combining ingredients comprising (a) water; (b) a source of free silver ions; and (c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent. [0014]
  • DETAILED DESCRIPTION
  • The inventors have unexpectedly discovered that a substantially non-colloidal solution made by combining ingredients comprising (a) water; (b) a source of free silver ions; and (c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent overcomes many of the limitations inherent in the aforementioned forms of ionic silver substances and has wide application in and on the body. [0015]
  • The inventive, substantially non-colloidal solution provides silver ion concentrations well above those typically provided by colloidal silver products. The production method provides a typically consistent formulation. The inventive formulation is highly stable, has many years of shelf life, and maintains its consistency and structure under a wide range of environmental conditions. Substantially wide concentration ranges of complexed silver are attainable without significantly compromising the desirable characteristics of the product. The composition of the invention efficiently provides for substantial mobility of the silver complex through the body and for controlled decomplexing of its silver content, whereupon it gradually releases silver as available free silver ions, upon introduction of the product to the body's chemistry internally through oral ingestion or upon topical application. [0016]
  • Further, the inventive, substantially non-colloidal solution is relatively nontoxic to the human body at typical doses. [0017]
  • The inventive substantially non-colloidal solutions are made from ingredients comprising water, a source of free silver ions; and a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent. [0018]
  • Water usable in the practice of this invention should be relatively pure. Suitable types of water include: deionized water, distilled water, reverse osmosis filtered water, reagent grade water and USP grade water suitable for use in pharmaceuticals. The water is desirably substantially free of contaminants, such as parasites, pathogens, chemical contaminants, and particulate contamination. [0019]
  • The source of silver ions may be virtually any compound or complex which includes silver ions as a constituent, from which those silver ions can be obtained in order to be complexed with the recited complexing agent or to become free silver ions as part of the inventive solution. Sources of silver ions comprise silver oxide, trisilver citrate, silver acetate, water soluble silver salts or any number of other sources of silver without departing from the scope of the invention. In a preferable embodiment, the source of silver ions is silver oxide (AgO). On complexing, silver oxide eliminates a superfluous counter ion, hydroxide, which is innocuous since hydroxide is already present in the solution. [0020]
  • The substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent serves primarily to provide a “controlled release” of biologically active silver ions. In the context of the invention, complexing agent may be taken to mean an ionic material with which silver ions are complexed in such a manner that the complexing agent forms a weak bond with the silver ions wherein the missing electron position which is a characteristic of the silver ion is filled by an electron of the complexing agent. The substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent may comprise a carboxylic acid, or a primary, secondary or tertiary amine. In the context of this invention, substantially non-toxic may be taken to mean that the recited complexing agent, when present in the inventive solution in usual amounts according to the invention, and when administered as part of the inventive solution in usual dosage amounts of the inventive solution, creates little or no toxic effects in a host to which the inventive solution is administered. In an embodiment, the substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent comprises amino acids or hydroxy acids. In a preferable embodiment, the amino acids comprise glycine, alanine, valine, leucine, isoleucine, methiorine, proline, phenylalanine, tryptophan, serine, threonine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, or histidine. In another preferable embodiment, the hydroxy acids comprise glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, or mandelic acid. In a more preferable embodiment, the citric acid comprises dibasic citrate. Citrate, a key constituent of the metabolic system, is aggressively drawn to the cells throughout the body and provides an efficient delivery system for spreading the silver through the body before decomplexing takes place and the silver is gradually released as available free silver ions. Also useful are acetic acid; certain crown ethers; primary, secondary or tertiary amines, such as ethanolamine, and other conventionally known substantially non-toxic, substantially thiol-free, substantially watersoluble complexing agents. [0021]
  • In an embodiment, the inventive substantially non-colloidal solution possesses greater than about twenty parts of silver per million parts of the non-colloidal solution. In the context of this invention, PPM is defined as parts of total silver to 1,000,000 parts of the total solution including the water base and all substances contained in it by weight. In another embodiment, the substantially non-colloidal solution possesses greater than about fifty parts of total silver per million parts of the non-colloidal solution. In a more preferable embodiment, the substantially non-colloidal solution posesses greater than or equal to about one hundred parts of total silver per million parts of the non-colloidal solution. Higher parts per million of total silver are desirable, as biological effectiveness increases as PPM free silver increases. [0022]
  • 100 PPM of silver is a desirable level for the total concentration of silver because it provides a highly effective concentration of silver yet the concentration is low enough to facilitate ease of measuring and dispensing the small dosages appropriate for small children and small animals. However, the amount of silver can vary substantially, within solubility limits, without departing from the scope of the invention, as long as the other elements are varied in relative proportion to the silver. In another embodiment, the inventive solution may be comprised of as little as about 10 PPM of silver or as much as about 10,000 PPM of silver without departing from the scope of the invention. [0023]
  • In an aspect of the invention, counter ions may be utilized. Such counter ions may be used to balance the charge present in the recited complexing agent, if necessary. Sources for counter ions suitable for use in this invention include those conventionally known sources of counter ions. Any suitable source of counter ions may be used where the complexing agent is such that a counter ion is required to maintain the electrical stability of the silver complex, so long as the counter ion used does not compete with the silver for the complexing agent. In a preferable embodiment, the source of counter-ions comprises potassium ions, or calcium ions. [0024]
  • In an aspect of the invention, the inventive non-colloidal solution possesses less than about ten weight percent of free silver based on the weight of total silver. In an aspect of the invention, the non-colloidal solution possesses less than about one weight percent of free silver based on the weight of total silver. In an aspect of the invention, the non-colloidal solution possesses less than about one-tenth of a weight percent of free silver based on the weight of total silver. A relatively low amount of free silver as compared to total silver (including non-free silver or complexed silver), is retained in a non-reacted state in the inventive solution, until released over time by the equilibrium driving force. This controlled release aspect of the inventive formulation is desirable, as activity is retained over time. [0025]
  • The preferred embodiment of the invention, containing a complex of citrate and silver with potassium as a counter ion, may include the following complex of ions in a solution of relatively pure water: [0026]
  • AgCOOCH2COHCOOCH2COOH−1(aq)
    Figure US20020025344A1-20020228-P00900
    Ag+(aq)+COOCH2COHCOOCH2COOH2−(aq)
  • In a preferable embodiment the inventive solution may be made by mixing silver oxide, citric acid and tripotassium citrate in an approximately 1*4 molar ratio, respectively, in sufficient pure water to produce a silver concentration of 100 parts per million. Other formulations which result in an approximate 1:2 molar ratio to an approximate 1:20 molar ratio of silver to dibasic citrate in no way depart from the scope of the invention. Generally, a preferable molar ratio (as dry ingredient or as solution) of silver to complexing agent is from about 1:1 to about 1:200, more preferably from about 1:1.5 to 1:50, most preferably from about 1:2 to about 1:20. [0027]
  • In another preferable embodiment, the free silver ions are present in the substantially non-colloidal solution in an anti-microbially effective amount. [0028]
  • The inventors have also produced the product following the general procedures described above but reducing the amounts of citric acid and of potassium citrate to half of the amounts described above. Numerous other variations can also be utilized with these starting ingredients provided that the ratio of citric acid to potassium citrate is generally maintained. Likewise, the amount of silver oxide may be substantially increased or decreased provided that a reasonably commensurate adjustment is made in the relative amounts of citric acid and of potassium citrate to silver oxide although, as demonstrated by the fact that the product was successfully produced upon changing the ratio of silver oxide to citric acid and to potassium citrate by [0029] 100%, substantial latitude exists with regard to that ratio.
  • As previously stated herein, numerous alternative source ingredients for yielding the silver ion, complexing agent, and counter ion for the preferred embodiment of the invention may also be used, requiring appropriately adjusted quantities, and, likewise, numerous other complexing agents and, if required, counter ion agents, may be selected as the constituents of the product as well, also requiring the appropriately adjusted quantities of the appropriate source ingredients necessary to produce the desired product. [0030]
  • It has often been claimed that ionic silver can kill over 650 disease-causing germs. The invention is absolutely harmless to the body when used in the low quantities needed for the antimicrobial action to occur, especially since the formulation provides an efficiently controlled, gradual release of free silver ions (provided that the complexing agent is nontoxic), requiring less silver ingestion in order to obtain the benefits of silver ion activity that other substances cannot render with substantially higher levels of silver ingestion. [0031]
  • Ionic silver is used for literally hundreds of conditions, including eye and ear infections, nose, sinus and gum infections, acne, sore throats, colds and flu, candida, bladder and vaginal infections, cuts and bums, many skin conditions, bug bites, fighting nail and skin fungus, healing sunburn, alleviating diaper rash and bed sores, providing a soothing skin treatment after shaving, and use as a mouth rinse. Body odors are caused by bacteria in the perspiration, which is often alleviated upon application of the invention, clearly demonstrating how effectively it kills bacteria. Ionic silver is also used for treating ulcers, both in fighting the bacteria that can aggravate an ulcer and in repairing the damaged stomach lining. Ionic silver is used for many severe conditions as well, including, for example, tuberculosis, Epstein-Barr Virus, Lyme Disease, Legionnaires' Disease, bronchitis, chicken pox, and numerous others. There are actually few germ-related conditions, or conditions requiring the repair of tissue, for which ionic silver is not used, since many claim it is not only effective in killing most bacteria but also many if not most fungus and viruses. Some reports indicate that it is also effective against a number of parasites that might invade the body. Ionic silver is also reported by some researchers to be effective at treating cancer and HIV. [0032]
  • Other uses for ionic silver range from purifying bottled water by placing some in the water, to retardation of food spoilage at home. Recent studies show that over 30 percent of bottled water contains bacteria levels above safety limits, which can readily be addressed with a few drops of the invention being added to the water. Spraying sliced fruits with the formulation of the invention can keep them fresh up to a week before spoilage, clearly demonstrating how effectively the invention kills bacteria on foods. It is also used to reverse existing contamination of foods. [0033]
  • Ionic silver is also considered by many to be very useful in oral irrigation systems designed for consumer use, that spray a fine stream of water in the mouth, in fighting infection and healing gums. Ionic silver is even reputed to be quite effective in facilitating the growth of hair in the local area on which it is topically applied. [0034]
  • In virtually all applications for which ionic silver is used, the advantages of a relatively high PPM of silver, a controlled, gradual release of available free silver ions and, in the case of the preferred embodiment of the invention, the benefit of citrate as a carrier on internal use together with the lack of toxicity and minimum likelihood of incurring mutated strains of germs, all serve to provide substantially superior benefits to those who would use the product for any of the myriad of conditions for which ionic silver would be used. [0035]
  • The product can readily be bottled or packaged with a variety of types of dispensers to further facilitate its usefulness. A bottle with a dropper is most convenient for eye drops, ear drops and nose drops. Alternatively, a plastic squeeze bottle can serve as a convenient dispenser for eye drops and ear drops, while the same with a nasal sprayer feature can readily facilitate use as a sinus and nasal spray. A spray dispenser such as with, for instance, a pump spray, makes it very convenient to apply the product externally and also provides a convenient and efficient method for oral use and internal ingestion. By disbursing the product upon spraying it in the mouth, such a spray facilitates absorption of the formula into the blood system through the tissue lining in the mouth. A spray dispenser also facilitates delivery of the product to the lungs as one may inhale while spraying the product towards the throat area. while inhaling. Because of the existence of a weak complex of silver and the existence of available free silver ions, along with the photoreactive qualities of silver, packaging should preferably be in an opaque glass container, in a stainless steel container, or in a polypropylene or polyethylene plastic container. Ideally, dispensers should be made of such materials as well. [0036]
  • Topically applying a gauze, cotton, sheer strip or other type of bandage or fabric that has been saturated with the product is another alternative for using the product. [0037]
  • The product can be used for humans as well as animals. When the complexing agent is a nontoxic material, the product is safe for children and pets. Thus, the invention has a wide range of potential uses for both medical and veterinary applications. [0038]
  • The product can also be applied to surfaces for killing germs thereon. For instance, it can be sprayed on counter tops, cutting boards, toilet seats, doorknobs, telephone handsets, etc. Upon contact with germ cells, the available free silver ions should react with and kill the germ cell, causing another silver ion to be decomplexed and released from the complexing agent and be made available. [0039]
  • The invention may be utilized in both the prevention and the treatment of disease. [0040]
  • Due to the efficient delivery of silver ions afforded by the invention, an individual may ingest the product on a daily basis as a preventative, achieving substantial levels of protection from germs, while remaining within extremely safe limits of daily and lifelong silver intake relative to the amount of silver contained in the product in the preferred embodiment. Studies show that the amount of silver in the average daily diet of adult Americans was depleted by as much as 85% between the early half of the 20th century and the latter part of that century. With the preferred embodiment of the invention, an individual consuming a substantial amount of the product on a daily basis in terms of potential health benefits would, in fact, be consuming no more silver than that amount which was depleted from the diets over that period of time. [0041]
  • EXAMPLES Example 1
  • Two and one-half liters of pure water were placed in a 5-gallon (1 9-liter functional capacity) carboy mounted on a magnetic stirrer with a Teflon-coated magnetic stir bar placed inside the carboy, turning on the stirrer at low speed, adding 6.7675 grams of citric acid anhydrous powder (reagent grade), 11.43 grams of potassium citrate monohydrate crystal (reagent grade), and 2.2450 grams of silver oxide powder (reagent grade), stirring at low speed for approximately 45 minutes. Next more water was slowly fed while continuing to stir at low speed for approximately an additional 15 minutes and stopping the water input when the level reaches approximately 8-9 liters. Then, the stir speed was turned to high and stirring continued for approximately an additional 30 minutes, filling the carboy to approximately the 18-liter mark, turning off the stirrer, opening the water input valve and stopping the water input at precisely the 19-liter mark, turning the stirrer back on to the high speed, and stirring for an additional 60 minutes. [0042]
  • Example 2
  • A 65-year old male developed conjunctivitis and obtained relief within less than five hours upon administering two drops of the solution of Example 1 in his eye. [0043]
  • Example 3
  • A sixteen-year old female had been suffering with acne for three or four years. A dermatologist had been treating her regularly to no avail. She applied six sprays of the solution of Example 1 three times per day to her face for three days and stopped using products from the dermatologist, and by the end of the third day the skin on her face cleared up almost completely. There was no dryness or redness any more. [0044]
  • Example 4
  • A 45-year old male had been diagnosed with lymphatic cancer and after taking an oral dose of one teaspoon of the solution of Example 1 per day for two months, tests showed that not a trace of the disease remained. [0045]
  • Example 5
  • A 31-year old male and a 28-year old male who work together in the same store had both come down with a full-blown flu. Both took fifteen drops of the solution of Example 1 in an oral dose, one time, and within a day-and-a-half both were completely free of any further symptoms. [0046]
  • Example 6
  • A one-year old male was diagnosed with a blocked tear duct in his left eye. Every day, he awoke with a green drainage that continued through the day. Two physicians recommended surgery. The boys mother administered only one drop of the solution of Example 1 in his eye each day for two days. The condition disappeared. Upon a follow-up nine months later, the condition had not returned. [0047]
  • Example 7
  • A 53-year old woman burned the back of her hand on a 450-degree oven. The burn was approximately an inch-and-a-quarter in diameter. After a week, it still had not begun to heal. The pain was still so bad that she could barely move her hand. She put two drops of the solution of Example 1 on it. By that same night, it had completely scabbed over and the entire circumference of the burn had already generated new tissue. The pain was completely gone and she had regained complete movement of her hand. Within about four more days of applying the invention, it was completely healed, without any scarring. [0048]
  • Example 8
  • A 61-year old male had developed a urinary tract infection. A urologist put him on sulfa drugs for twenty days. He suffered through a week of constant nausea, at which point he threw out the remaining pills. He then began to ingest 30 drops of the solution of Example 1 per day, and after three days the infection was no longer detectable. [0049]
  • Example 9
  • A forty-four-year old male developed abscesses surrounding two wisdom teeth. Three oral surgeons told him the teeth had to come out. He applied approximately one teaspoon of the solution of Example 1 each to each of the two affected areas. By the next day, the infections were undetectable and the pain was gone. A follow-up eleven months later showed that it had not returned. [0050]
  • Example 10
  • A twenty-four-year old woman developed a vaginal infection. The doctor's prescription didn't help after almost two weeks. She then mixed one half-teaspoon of the solution of Example 1 in pure water and used the mixture as a douche, and the discomfort disappeared almost immediately and had not returned upon a follow-up three weeks later. [0051]

Claims (17)

1. A substantially non-colloidal solution made by combining ingredients comprising:
(a) water;
(b) a source of free silver ions; and
(c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent.
2. The substantially non-colloidal solution of claim 1, wherein the non-colloidal solution possesses less than about ten weight percent of free silver based on the weight of total silver.
3. The substantially non-colloidal solution of claim 2, wherein the non-colloidal solution possesses less than about one weight percent of free silver based the weight of total silver.
4. The substantially non-colloidal solution of claim 3, wherein the non-colloidal solution possesses less than about one-tenth of a percent by weight of free silver based on the weight of total silver.
5. The substantially non-colloidal solution of claim 1, wherein the non-colloidal solution possesses greater than about twenty parts of total silver per million parts of the non-colloidal solution.
6. The substantially non-colloidal solution of claim 5, wherein the non-colloidal solution possesses greater than about fifty parts of total silver per million parts of the non-colloidal solution.
7. The substantially non-colloidal solution of claim 6, wherein the non-colloidal solution possesses greater than or equal to about one hundred parts of total silver per million parts of the non-colloidal solution.
8. The substantially non-colloidal solution of claim 1, wherein the source of free silver ions comprises silver oxide, trisilver citrate, or silver acetate.
9. The substantially non-colloidal solution of claim 8, wherein the source of free silver ions comprises silver oxide.
10. The substantially non-colloidal solution of claim 1, wherein the substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent comprises a carboxylic acid, or a primary, secondary or tertiary amine.
11. The substantially non-colloidal solution of claim 10, wherein the substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent comprises amino acids or hydroxy acids.
12. The substantially non-colloidal solution of claim 11, wherein the amino acids comprise glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tryptophan, serine, threonine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, or histidine.
13. The substantially non-colloidal solution of claim 12, wherein the hydroxy acids comprise glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, or mandelic acid.
14. The substantially non-colloidal solution of claim 13, wherein the citric acid is dibasic citrate.
15. The substantially non-colloidal solution of claim 1, wherein the free silver ions are present in the substantially non-colloidal solution in an anti-microbially effective amount.
16. The substantially non-colloidal solution of claim 1, wherein the ingredients further comprise a source of counter-ions.
17. The substantially non-colloidal solution of claim 1, wherein the source of counter-ions comprises potassium ions, or calcium ions.
US09/796,242 1998-11-09 2001-02-28 Ionic silver complex Abandoned US20020025344A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US09/796,242 US20020025344A1 (en) 1998-11-09 2001-02-28 Ionic silver complex
US10/175,260 US20020150628A1 (en) 1998-11-09 2002-06-18 Ionic silver complex
US10/383,345 US6838095B2 (en) 1998-11-09 2003-03-07 Ionic silver complex
US11/028,840 US20050118281A1 (en) 1998-11-09 2005-01-04 Ionic silver complex

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10771098P 1998-11-09 1998-11-09
US43515899A 1999-11-05 1999-11-05
US09/796,242 US20020025344A1 (en) 1998-11-09 2001-02-28 Ionic silver complex

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US43515899A Continuation 1998-11-09 1999-11-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/175,260 Continuation US20020150628A1 (en) 1998-11-09 2002-06-18 Ionic silver complex

Publications (1)

Publication Number Publication Date
US20020025344A1 true US20020025344A1 (en) 2002-02-28

Family

ID=22318046

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/796,242 Abandoned US20020025344A1 (en) 1998-11-09 2001-02-28 Ionic silver complex
US10/175,260 Abandoned US20020150628A1 (en) 1998-11-09 2002-06-18 Ionic silver complex
US10/383,345 Expired - Lifetime US6838095B2 (en) 1998-11-09 2003-03-07 Ionic silver complex
US11/028,840 Abandoned US20050118281A1 (en) 1998-11-09 2005-01-04 Ionic silver complex

Family Applications After (3)

Application Number Title Priority Date Filing Date
US10/175,260 Abandoned US20020150628A1 (en) 1998-11-09 2002-06-18 Ionic silver complex
US10/383,345 Expired - Lifetime US6838095B2 (en) 1998-11-09 2003-03-07 Ionic silver complex
US11/028,840 Abandoned US20050118281A1 (en) 1998-11-09 2005-01-04 Ionic silver complex

Country Status (7)

Country Link
US (4) US20020025344A1 (en)
EP (1) EP1128824A1 (en)
JP (2) JP2002529411A (en)
AU (1) AU776212B2 (en)
BR (1) BR9915174A (en)
NZ (1) NZ512267A (en)
WO (1) WO2000027390A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192298A1 (en) * 2001-04-23 2002-12-19 Burrell Robert Edward Treatment of acne
US20030180378A1 (en) * 2000-07-27 2003-09-25 Gillis Scott H. Dry powders of metal-containing compounds
US20030203046A1 (en) * 2000-07-27 2003-10-30 Burrell Robert E. Solutions and aerosols of metal-containing compounds
US20030206966A1 (en) * 2000-07-27 2003-11-06 Burrell Robert E. Methods of inducing apoptosis and modulating metalloproteinases
US6692773B2 (en) 2000-07-27 2004-02-17 Nucryst Pharmaceuticals Corp. Treatment of hyperproliferative skin disorders and diseases
US6719987B2 (en) 2000-04-17 2004-04-13 Nucryst Pharmaceuticals Corp. Antimicrobial bioabsorbable materials
US6723350B2 (en) 2001-04-23 2004-04-20 Nucryst Pharmaceuticals Corp. Lubricious coatings for substrates
US20040110738A1 (en) * 2002-10-22 2004-06-10 Gillis Scott H. Prophylactic treatment methods
US20040129112A1 (en) * 2000-07-27 2004-07-08 Gillis Scott H. Metal-containing materials
US20040131698A1 (en) * 2000-07-27 2004-07-08 Gillis Scott H. Methods of treating conditions using metal-containing materials
US20040176312A1 (en) * 2002-04-23 2004-09-09 Gillis Scott H. Treatment of ungual and subungual diseases
US20040191329A1 (en) * 2000-07-27 2004-09-30 Burrell Robert E. Compositions and methods of metal-containing materials
US20050089539A1 (en) * 2003-09-09 2005-04-28 3M Innovative Properties Company Antimicrobial compositions and methods
US7001617B2 (en) 2001-04-23 2006-02-21 Nueryst Pharmaceuticals Corp. Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
US20060051385A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Cationic antiseptic compositions and methods of use
US20060052452A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Phenolic antiseptic compositions and methods of use
US20060051384A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Antiseptic compositions and methods of use
US7137968B1 (en) 2000-03-13 2006-11-21 Nucryst Pharmaceuticals Corp. Transcutaneous medical device dressings and method of use
US20060263444A1 (en) * 2005-05-19 2006-11-23 Xintian Ming Antimicrobial composition
US20080014278A1 (en) * 2006-06-30 2008-01-17 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
US20080229929A1 (en) * 2007-03-22 2008-09-25 Ken Marcoon Antimicrobial filtration article
US20080287538A1 (en) * 2005-03-10 2008-11-20 Scholz Matthew T Antimicrobial Compositions and Methods
US20080292721A1 (en) * 2007-05-18 2008-11-27 Crudden Joseph J Bioactive acid agrichemical compositrions and use thereof
US7470437B2 (en) 2000-07-27 2008-12-30 Nucryst Pharmaceuticals Corp. Methods of treating conditions with a metal-containing material
US20090005339A1 (en) * 2005-03-10 2009-01-01 Scholz Matthew T Methods of Treating Ear Infections
US20090010981A1 (en) * 2000-08-31 2009-01-08 Bio-Gate Ag Antimicrobial material for implanting in bones
US20090162448A1 (en) * 2007-12-20 2009-06-25 Nucryst Pharmaceuticals Corp. Metal Carbonate Particles and Methods of Making Thereof
US20090226541A1 (en) * 2005-03-10 2009-09-10 3M Innovative Properties Company Methods of reducing microbial contamination
US9295254B2 (en) 2011-12-08 2016-03-29 Sciessent Llc Nematicides
CN114766520A (en) * 2022-05-20 2022-07-22 千藤(南京)环保科技有限公司 Citric acid three-silver composition, preparation method and application

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1041879B2 (en) * 1997-10-10 2012-03-21 Pure Bioscience Disinfectant and method of making
NZ512267A (en) * 1998-11-09 2003-11-28 Ira Jay Newman Ionic silver complex
US7261905B2 (en) * 1999-04-07 2007-08-28 Pure Bioscience Disinfectant and method of making
US6242009B1 (en) * 1999-04-20 2001-06-05 Kareem I. Batarseh Microbicidal formulations and methods to control microorganisms
US6890953B2 (en) * 2000-04-06 2005-05-10 Innovative Medical Services Process for treating water
US6630172B2 (en) 2001-01-22 2003-10-07 Kareem I. Batarseh Microbicidal composition containing potassium sodium tartrate
US20040044073A1 (en) * 2002-08-31 2004-03-04 Innovative Medical Services Composition and process for treating acne
US7435438B1 (en) * 2003-05-16 2008-10-14 Pure Bioscience Disinfectant and method of use
DK200301128A (en) * 2003-08-05 2005-02-06 Thomsen Joern Oddershede Grant Preparation
CA2536955A1 (en) * 2003-08-28 2005-03-10 Pure Bioscience Silver dihydrogen citrate compositions comprising a second antimicrobial agent
SE528045C2 (en) * 2004-02-23 2006-08-15 Polygiene Ab Use of a plastic composition to provide a surface with antivirus activity
JP5586816B2 (en) 2004-03-15 2014-09-10 大正製薬株式会社 Composition containing zinc compound
US20050249818A1 (en) * 2004-05-03 2005-11-10 Sawan Samuel P Polycationic antimicrobial therapeutic
US20060115440A1 (en) * 2004-09-07 2006-06-01 Arata Andrew B Silver dihydrogen citrate compositions
US20060051430A1 (en) * 2004-09-07 2006-03-09 Arata Andrew B Silver dihydrogen citrate compositions
US8048870B2 (en) * 2005-01-11 2011-11-01 Batarseh Kareem I Apoptosis-inducing antineoplastic silver (I) coordination complexes
US20060216322A1 (en) * 2005-03-25 2006-09-28 Kenko Corporation Feed composition and method for breeding animals
US20090074881A1 (en) * 2006-05-02 2009-03-19 Bioneutral Laboratories Corporation Usa Antimicrobial cidality formulations with residual efficacy, uses thereof, and the preparation thereof
EP1938690B1 (en) * 2006-12-22 2013-10-23 Preentec AG Sterilising and preserving fluids
US9132296B2 (en) 2007-05-17 2015-09-15 Ag Essence Antimicrobial solution and methods of making and using the same
US9393261B2 (en) * 2011-07-22 2016-07-19 Body Glide LLC Antimicrobial anti-chafing chelated silver oxide compound
BRPI0802626A2 (en) * 2008-06-06 2011-08-30 Pure Bioscience dihydrogen silver citrate agricultural applications
DE102008031927B4 (en) 2008-07-08 2017-09-14 Beiersdorf Ag Cosmetic preparations with passivated silver
US8399028B2 (en) * 2008-08-14 2013-03-19 Exciton Technologies Inc. Antimicrobial silver solutions
US8535729B2 (en) * 2008-12-05 2013-09-17 The Clorox Company Natural silver disinfectant compositions
JP6001906B2 (en) * 2012-04-04 2016-10-05 株式会社Powerful Trade Limited Japan Method for producing bacteriostatic bactericidal deodorant composition for rubble and bacteriostatic bactericidal deodorant composition for rubble
US11547116B2 (en) * 2012-12-12 2023-01-10 William Wingfield Metal oxide compounds and infusion into polymer compounds
US11618696B2 (en) 2013-08-15 2023-04-04 Applied Silver, Inc. Antimicrobial batch dilution system
US10640403B2 (en) 2013-08-15 2020-05-05 Applied Silver, Inc. Antimicrobial batch dilution system
US10000881B2 (en) 2013-12-06 2018-06-19 Applied Silver, Inc. Method for antimicrobial fabric application
MX2016009696A (en) * 2014-01-27 2017-03-27 Aidance Skincare & Topical Solutions Llc Topical antibiotic formulations.
US10808047B2 (en) 2015-08-21 2020-10-20 G&P Holding, Inc. Silver and copper itaconates and poly itaconates
US20170050870A1 (en) 2015-08-21 2017-02-23 Applied Silver, Inc. Systems And Processes For Treating Textiles With An Antimicrobial Agent
WO2017067852A1 (en) * 2015-10-21 2017-04-27 Unilever N.V. An antimicrobial composition
EP3454660B1 (en) 2016-05-12 2022-04-06 Applied Silver Inc. Articles and methods for dispensing metal ions into laundry systems
EP3565412A4 (en) 2016-10-31 2020-12-30 Applied Silver Inc. Dispensing of metal ions into batch laundry washers and dryers
US10760207B2 (en) 2017-03-01 2020-09-01 Applied Silver, Inc. Systems and processes for treating textiles with an antimicrobial agent
EA029076B1 (en) * 2017-03-22 2018-02-28 Учреждение Белорусского государственного университета "Научно-исследовательский институт физико-химических проблем" (НИИ ФХП БГУ) Antimicrobial agent
KR102123206B1 (en) * 2020-02-19 2020-06-16 곽병상 Antimicrobial Composition Comprising Silver Compound and Complexing Agent
CN111205312B (en) * 2020-03-31 2021-03-16 榫卯科技服务(温州)有限公司 Antibacterial rare earth complex material and preparation method thereof
KR102223638B1 (en) * 2020-07-28 2021-03-04 곽병상 PSA stabilizer in blood comprising antimicrobial composition containing silver compound and complexing agent and Panax notoginseng extract
WO2022031537A1 (en) * 2020-08-03 2022-02-10 Reed Frank Joseph Compositions for prevention and treatment of rsv and coronavirus infection

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE400040A (en) *
NL147015B (en) 1971-02-16 1975-09-15 Basf Ag PROCESS FOR THE PREPARATION OF A PREPARATION FOR KEEPING CUT FLOWERS IN FRESH CONDITION.
US3826639A (en) * 1971-02-16 1974-07-30 Basf Ag Agent for keeping cut flowers fresh
DE2260566A1 (en) * 1972-12-11 1974-06-12 Christoffers Maschinenfab Gmbh WIRE DRAWING MACHINE (SCHOTTWAND)
FR2399847A1 (en) * 1977-08-11 1979-03-09 Nat Res Lab ANTIMICROBIAL AGENTS AND THEIR APPLICATIONS
US4055655A (en) 1975-07-21 1977-10-25 National Research Laboratories Complexes of heavy metal ions and polyfunctional organic ligands used as antimicrobial agents
JPS5437824A (en) * 1977-08-30 1979-03-20 Nat Risaachi Lab Bacteriocide comprising metal complex compound
CA1218600A (en) * 1982-12-06 1987-03-03 Gerald L. Maurer Methods and compositions for treating inflammation or arthritis
JPS59126492A (en) * 1982-12-24 1984-07-21 Fujitsu Ltd Liquid crystal composition
JPH0622540B2 (en) * 1985-12-18 1994-03-30 株式会社祥光化学研究所 Structure with deodorant and antibacterial activity
CH673225A5 (en) * 1986-04-22 1990-02-28 Sanosil Ag
JPH02111709A (en) * 1988-10-20 1990-04-24 Agency Of Ind Science & Technol Powdery antibacterial and antimycotic agent and production thereof
US5032612A (en) * 1990-05-25 1991-07-16 Smolko Milan J Non-smoking aid
DE4123292C2 (en) 1991-07-13 1996-01-25 Hungerbach Chemotechnik Gmbh Oral hygiene and use of a silver colloid stabilized hydrogen peroxide solution in oral hygiene products
WO1993005794A1 (en) * 1991-09-20 1993-04-01 Similasan Corp. Preservative for pharmaceutical products
US5322520A (en) 1992-11-12 1994-06-21 Implemed, Inc. Iontophoretic structure for medical devices
JP3595352B2 (en) * 1993-02-01 2004-12-02 株式会社サンギ Antitumor and antibacterial agents
GB9309387D0 (en) * 1993-05-06 1993-06-16 Wellcome Found Nitric oxide scavengers
WO1995012602A1 (en) 1993-11-05 1995-05-11 Meiji Milk Products Co., Ltd. Antibacterial, antifungal and antiviral agent
EP0804877B1 (en) 1994-10-05 2003-05-21 Toto Ltd. Antimicrobial solid material, process for producing the same, and method of utilizing the same
ZA962939B (en) 1995-04-12 1997-10-13 Quest Int Oral care compositions.
JP3449123B2 (en) * 1996-07-22 2003-09-22 旭硝子株式会社 Coating solution for forming low-resistance film or low-refractive-index film, and method for producing low-resistance film or low-reflection low-refractive-index film
US5688981A (en) * 1996-11-21 1997-11-18 Hampshire Chemical Corp. Ethylenediaminetriacetic acid and N-acyl ethylenediaminetriacetic acid silver chelating agents and surfactants
US5785972A (en) 1997-01-10 1998-07-28 Tyler; Kathleen A. Colloidal silver, honey, and helichrysum oil antiseptic composition and method of application
US5932251A (en) 1997-04-23 1999-08-03 Kirkpatrick; Carole M. Hair growth promoter and method of using same
NL1005965C2 (en) * 1997-05-05 1998-11-13 Tevan Chemie B V Disinfectant formulation.
EP1041879B2 (en) * 1997-10-10 2012-03-21 Pure Bioscience Disinfectant and method of making
JP2000016905A (en) * 1998-07-01 2000-01-18 Tokuriki Kagaku Kenkyusho:Kk Antibacterial-fungal agent and antibacterial-fungal material
NZ512267A (en) * 1998-11-09 2003-11-28 Ira Jay Newman Ionic silver complex
EP1036511A3 (en) 1999-03-15 2001-08-29 Ralf M. Kern Method for preservation and composition for use therewith

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7137968B1 (en) 2000-03-13 2006-11-21 Nucryst Pharmaceuticals Corp. Transcutaneous medical device dressings and method of use
US20070010778A1 (en) * 2000-03-13 2007-01-11 Nucryst Pharmaceuticals Corp., A Canadian Corporation Transcutaneous medical device dressings and method of use
US6719987B2 (en) 2000-04-17 2004-04-13 Nucryst Pharmaceuticals Corp. Antimicrobial bioabsorbable materials
US20040129112A1 (en) * 2000-07-27 2004-07-08 Gillis Scott H. Metal-containing materials
US6692773B2 (en) 2000-07-27 2004-02-17 Nucryst Pharmaceuticals Corp. Treatment of hyperproliferative skin disorders and diseases
US20030206966A1 (en) * 2000-07-27 2003-11-06 Burrell Robert E. Methods of inducing apoptosis and modulating metalloproteinases
US7470437B2 (en) 2000-07-27 2008-12-30 Nucryst Pharmaceuticals Corp. Methods of treating conditions with a metal-containing material
US6989157B2 (en) 2000-07-27 2006-01-24 Nucryst Pharmaceuticals Corp. Dry powders of metal-containing compounds
US20040131698A1 (en) * 2000-07-27 2004-07-08 Gillis Scott H. Methods of treating conditions using metal-containing materials
US7427416B2 (en) 2000-07-27 2008-09-23 Nucryst Pharmaceuticals Corp. Methods of treating conditions using metal-containing materials
US20080014286A1 (en) * 2000-07-27 2008-01-17 Nucryst Pharmaceuticals Corp., A Canada Corporation Metal-containing materials
US20040191329A1 (en) * 2000-07-27 2004-09-30 Burrell Robert E. Compositions and methods of metal-containing materials
US7255881B2 (en) 2000-07-27 2007-08-14 Nucryst Pharmaceuticals Corp. Metal-containing materials
US20030203046A1 (en) * 2000-07-27 2003-10-30 Burrell Robert E. Solutions and aerosols of metal-containing compounds
US20030180378A1 (en) * 2000-07-27 2003-09-25 Gillis Scott H. Dry powders of metal-containing compounds
US20090010981A1 (en) * 2000-08-31 2009-01-08 Bio-Gate Ag Antimicrobial material for implanting in bones
US20060083777A1 (en) * 2001-04-23 2006-04-20 Nucryst Pharmaceuticals Corp. Treatment of acne
US20020192298A1 (en) * 2001-04-23 2002-12-19 Burrell Robert Edward Treatment of acne
US7008647B2 (en) 2001-04-23 2006-03-07 Nucryst Pharmaceuticals Corp. Treatment of acne
US6723350B2 (en) 2001-04-23 2004-04-20 Nucryst Pharmaceuticals Corp. Lubricious coatings for substrates
US20040157073A1 (en) * 2001-04-23 2004-08-12 Nucryst Pharmaceuticals Corp., A Alberta, Canada Corporation Lubricious coatings for substrates
US7001617B2 (en) 2001-04-23 2006-02-21 Nueryst Pharmaceuticals Corp. Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
US6939568B2 (en) 2001-04-23 2005-09-06 Nucryst Pharmaceuticals Corp. Treatment of inflammatory skin conditions
US20060083792A1 (en) * 2001-04-23 2006-04-20 Nucryst Pharmaceuticals Corp. Therapeutic treatments using the direct application of antimicrobial metal compositions
US7087249B2 (en) 2001-04-23 2006-08-08 Nucryst Pharmaceuticals Corp. Treatment of mucosal membranes
US20060204591A1 (en) * 2001-04-23 2006-09-14 Nucryst Pharamaceuticals Corp., A Canadian Corporation Treatment of mucosal membranes
US6989156B2 (en) 2001-04-23 2006-01-24 Nucryst Pharmaceuticals Corp. Therapeutic treatments using the direct application of antimicrobial metal compositions
US20040176312A1 (en) * 2002-04-23 2004-09-09 Gillis Scott H. Treatment of ungual and subungual diseases
US7201925B2 (en) 2002-04-23 2007-04-10 Nueryst Pharmaceuticals Corp. Treatment of ungual and subungual diseases
US20040110738A1 (en) * 2002-10-22 2004-06-10 Gillis Scott H. Prophylactic treatment methods
US20050089539A1 (en) * 2003-09-09 2005-04-28 3M Innovative Properties Company Antimicrobial compositions and methods
US8512723B2 (en) 2003-09-09 2013-08-20 3M Innovative Properties Company Antimicrobial compositions and methods
US10471036B2 (en) 2003-09-09 2019-11-12 3M Innovative Properties Company Antimicrobial compositions and methods
US10016501B2 (en) 2004-09-07 2018-07-10 3M Innovative Properties Company Cationic antiseptic compositions and methods of use
US20060052452A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Phenolic antiseptic compositions and methods of use
US9028852B2 (en) 2004-09-07 2015-05-12 3M Innovative Properties Company Cationic antiseptic compositions and methods of use
US20060051384A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Antiseptic compositions and methods of use
US20060051385A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Cationic antiseptic compositions and methods of use
US8198326B2 (en) 2004-09-07 2012-06-12 3M Innovative Properties Company Phenolic antiseptic compositions and methods of use
US10918618B2 (en) 2005-03-10 2021-02-16 3M Innovative Properties Company Methods of reducing microbial contamination
US9826770B2 (en) 2005-03-10 2017-11-28 3M Innovative Properties Company Antimicrobial compositions comprising esters of hydroxycarboxylic acids
US20080287538A1 (en) * 2005-03-10 2008-11-20 Scholz Matthew T Antimicrobial Compositions and Methods
US8476319B2 (en) 2005-03-10 2013-07-02 3M Innovative Properties Company Methods of treating ear infections
US20090226541A1 (en) * 2005-03-10 2009-09-10 3M Innovative Properties Company Methods of reducing microbial contamination
US20090005339A1 (en) * 2005-03-10 2009-01-01 Scholz Matthew T Methods of Treating Ear Infections
US20060263444A1 (en) * 2005-05-19 2006-11-23 Xintian Ming Antimicrobial composition
US20080014278A1 (en) * 2006-06-30 2008-01-17 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
US20080014247A1 (en) * 2006-06-30 2008-01-17 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
US20080044491A1 (en) * 2006-06-30 2008-02-21 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
US20080050452A1 (en) * 2006-06-30 2008-02-28 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
US20080229929A1 (en) * 2007-03-22 2008-09-25 Ken Marcoon Antimicrobial filtration article
US7520923B2 (en) 2007-03-22 2009-04-21 Mvp Textiles & Apparel, Inc. Antimicrobial filtration article
US20090232962A1 (en) * 2007-03-22 2009-09-17 Ken Marcoon Antimicrobial filtration article
US7744681B2 (en) 2007-03-22 2010-06-29 Mvp Textiles & Apparel, Inc. Antimicrobial filtration article
AU2008254482B2 (en) * 2007-05-18 2013-11-28 Sciessent, Llc Bioactive acid agrichemical compositions and use thereof
US8895044B2 (en) * 2007-05-18 2014-11-25 Sciessent, Llc Food preservation compositions and methods
US20080292721A1 (en) * 2007-05-18 2008-11-27 Crudden Joseph J Bioactive acid agrichemical compositrions and use thereof
US9034393B2 (en) * 2007-05-18 2015-05-19 Sciessent Llc Bioactive acid agrichemical compositions and use thereof
US20080292722A1 (en) * 2007-05-18 2008-11-27 Crudden Joseph J Food preservation compositions and methods
US20080299222A1 (en) * 2007-05-18 2008-12-04 Crudden Joseph J Bioactive agrichemical compositions and use thereof
US20130004587A1 (en) * 2007-05-18 2013-01-03 Sciessent Llc Bioactive Acid Agrichemical Compositions and Use Thereof
US20090047364A1 (en) * 2007-05-18 2009-02-19 Crudden Joseph J Disinfecting methods and compositions
US20090162448A1 (en) * 2007-12-20 2009-06-25 Nucryst Pharmaceuticals Corp. Metal Carbonate Particles and Methods of Making Thereof
US8865227B2 (en) 2007-12-20 2014-10-21 Smith & Nephew (Overseas) Limited Metal carbonate particles and methods of making thereof
US9295254B2 (en) 2011-12-08 2016-03-29 Sciessent Llc Nematicides
CN114766520A (en) * 2022-05-20 2022-07-22 千藤(南京)环保科技有限公司 Citric acid three-silver composition, preparation method and application

Also Published As

Publication number Publication date
JP2002529411A (en) 2002-09-10
BR9915174A (en) 2001-11-06
NZ512267A (en) 2003-11-28
US20050118281A1 (en) 2005-06-02
WO2000027390A1 (en) 2000-05-18
US20020150628A1 (en) 2002-10-17
AU1470100A (en) 2000-05-29
AU776212B2 (en) 2004-09-02
JP5722757B2 (en) 2015-05-27
EP1128824A1 (en) 2001-09-05
JP2012107014A (en) 2012-06-07
US6838095B2 (en) 2005-01-04
US20030147970A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
US6838095B2 (en) Ionic silver complex
US6709681B2 (en) Acidified nitrite as an antimicrobial agent
US3830908A (en) Anti-microbial compositions utilizing allantoin compounds and complexes
CN101711761A (en) Compositions for prevention and treatment of cold and influenza-like symptoms and use methods thereof.
AU2002312416A1 (en) Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions
AU758264B2 (en) Inorganic nitrite and organic acid in combination as topical antiviral composition
WO1999037295A1 (en) Method and composition for skin treatment
US20080020025A1 (en) Composition for wound care and method of using same
US20110287113A1 (en) Treatment of psoriasis
US8513225B2 (en) Composition and method for topical treatment of skin lesions
WO2008104076A1 (en) Electrocolloidal silver and echinacea root antimicrobial formulation
WO2000054593A1 (en) Iodine preparation compositon
JP3899267B2 (en) Use of tosylchloramide to treat skin, mucous membrane, organ or tissue disorders
CN102670648A (en) Liquid iodine disinfectant, preparation method and used container thereof
US20040009964A1 (en) Compositions and methods for the treatment of matrix metalloproteinase-related diseases
EP0000670A1 (en) Therapeutic selenium compositions and the use thereof
US20180228837A1 (en) Stable iodine solutions with medical applications
MXPA01005900A (en) Ionic silver complex
JPH10265405A (en) Skin preparation containing insulin for external use
JPS5936609A (en) Adhesive application pharmaceutical
CN102846661A (en) Compound nano-silver emulsifiable paste and preparation method thereof
CN110638832A (en) Nano-silver lidocaine antibacterial pain-relieving plaster and preparation method thereof
CN112352789A (en) Preparation method of silver chloride ion symbiotic disinfection concentrated solution
CN102727422A (en) Nano-silver emulsifiable paste and its preparation method
MXPA01009277A (en) Iodine preparation compositon

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION